Trial Profile
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary) ; Ravulizumab (Primary)
- Indications Aplastic anaemia; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease
- 29 Feb 2024 Planned number of patients changed from 6000 to 5950.
- 29 Feb 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2024.
- 29 Feb 2024 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2024.